Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study-Reference-Cited by-同舟云学术

Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study

Published:2015-08-26 Issue:9 Volume:67 Page:2487-2494
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Davies Rebecca¹,Southwood Taunton R.²,Kearsley‐Fleet Lianne¹,Lunt Mark¹,Hyrich Kimme L.³,

Affiliation:

1. University of Manchester and Manchester Academic Health Science CentreManchester UK

2. University of Birmingham and Birmingham Children's HospitalBirmingham UK

3. University of Manchester, Manchester Academic Health Science Centre, and Central Manchester University Hospitals NHS Foundation TrustManchester UK

Funder

British Society for Paediatric and Adolescent Rheumatology

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.39197

Reference25 articles.

1. Juvenile idiopathic arthritis

2. Safety and Efficacy of Etanercept in a Cohort of Patients with Juvenile Idiopathic Arthritis Under 4 Years of Age

3. Serious musculoskeletal infections in children receiving anti-tumor necrosis factor-α therapy: a case series

4. Biologic response modifiers to decrease inflammation: Focus on infection risks

5. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-life data of etanercept efficacy and safety in juvenile idiopathic arthritis: a 24-month retrospective study at a single center;Expert Opinion on Biological Therapy;2024-08-02

2. How Safe Are Biological Agents in Pediatric Rheumatology?;Turkish Archives of Pediatrics;2024-03-01

3. Update on the systemic management of noninfectious uveitis in children and adolescents;Survey of Ophthalmology;2024-01

4. Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis;Rheumatology;2022-09-15

5. Are infections in children with juvenile idiopathic arthritis more frequent than in healthy children? A prospective multicenter observational study;Frontiers in Pediatrics;2022-08-11